CA
NZ
UK
AU
IND
US
…
InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments, Online sales and Other Operations. The company develops a cannabidiol (CBD)-loaded liposome drug delivery platform (CBD-LPT), which is in the preclinical trial phase to treat chronic pain management for human and veterinary health sectors. It also offers a pain-relieving topical composition, as well as compositions for the treatment of hemorrhoid, psoriasis of the scalp, vaginal atrophy, and diabetic symptoms. The company is also involved in development, manufacture, and marketing of cosmetic products. InnoCan Pharma Corporation was founded in 2017 and is headquartered in Calgary, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
InnoCan Pharma Corporation appears positioned as a biopharmaceutical company developing cannabinoid-based therapeutics and related drug-delivery technologies for medical and cosmetic applications. Long-term growth drivers may include progress in R&D programs, potential collaborations or licensing, and broader clinical and regulatory acceptance of cannabinoid-based treatments that could support commercialization. Investors may find exposure to a niche drug-delivery and cannabinoid-focused pipeline attractive for diversified small-cap biotech allocation.
Material investment risks include early-stage development with no assured revenues, limited public disclosure and liquidity as an OTCQB-listed issuer, regulatory and legal uncertainty around cannabinoid products, and execution and financing risk common to small biotechs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-10-31 |
| Income before tax | 0.09M | 0.92M | -4.03M | -3.89M | -3.89M |
| Minority interest | -0.78M | -1.57M | -0.45M | 0.12M | 0.12M |
| Net income | -1.12M | -1.83M | -4.70M | -3.76M | -3.76M |
| Selling general administrative | 24.25M | 4.75M | 3.08M | 3.98M | 6.85M |
| Selling and marketing expenses | - | 21.13M | 10.91M | 2.86M | - |
| Gross profit | 23.93M | 26.19M | 11.98M | 2.11M | 2.11M |
| Reconciled depreciation | 0.04M | 0.04M | 0.03M | 0.04M | 0.04M |
| Ebit | - | -1.25M | -3.80M | -3.73M | - |
| Ebitda | - | -1.21M | -3.77M | -3.70M | -3.85M |
| Depreciation and amortization | - | 0.04M | 0.03M | 0.03M | - |
| Operating income | -1.25M | -1.25M | 3.80M | -6.27M | -6.27M |
| Other operating expenses | - | 30.68M | 9.85M | 8.82M | - |
| Interest expense | 0.00M | 0.01M | 0.00M | 0.00M | 0.00M |
| Tax provision | 0.43M | 1.18M | 0.21M | 0.00M | 0.00M |
| Interest income | - | 0.00M | 0.02M | 0.02M | 0.02M |
| Net interest income | -0.00M | -0.01M | 0.02M | 0.02M | 0.02M |
| Income tax expense | - | 1.18M | 0.21M | 0.00M | - |
| Total revenue | 26.61M | 29.44M | 13.66M | 2.56M | 2.56M |
| Total operating expenses | 27.87M | 27.43M | 8.18M | 8.37M | 8.82M |
| Cost of revenue | 2.68M | 3.25M | 1.68M | 0.45M | 0.45M |
| Total other income expense net | 1.34M | 2.17M | -7.84M | 2.38M | 2.36M |
| Net income from continuing ops | -0.34M | -0.26M | -4.25M | -3.89M | -3.89M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-10-31 |
| Total assets | 10.52M | 9.26M | 6.94M | 6.98M | 6.98M |
| Other current assets | - | 0.14M | 0.92M | 0.74M | - |
| Total liab | 2.29M | 2.24M | 2.55M | 0.75M | 0.75M |
| Total stockholder equity | 5.60M | 7.02M | 4.39M | 6.22M | 6.39M |
| Other current liab | 0.39M | 2.04M | 2.41M | 0.62M | 0.30M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -36.03M | -34.91M | -33.07M | -28.37M | -28.37M |
| Cash | 6.69M | 5.01M | 3.88M | 4.95M | 4.95M |
| Total current liabilities | 1.35M | 2.24M | 2.54M | 0.73M | 0.73M |
| Current deferred revenue | - | - | - | 0.32M | - |
| Net debt | - | -5.00M | -3.85M | -4.91M | - |
| Short term debt | - | 0.01M | 0.02M | 0.01M | - |
| Short long term debt total | - | 0.01M | 0.03M | 0.03M | - |
| Other stockholder equity | - | 40.08M | 37.18M | 34.77M | - |
| Total current assets | 10.44M | 9.15M | 6.80M | 6.88M | 6.88M |
| Net receivables | - | 0.69M | 0.25M | 0.24M | 0.01M |
| Long term debt | 0.93M | - | - | - | - |
| Inventory | 2.18M | 3.32M | 1.74M | 1.13M | 1.13M |
| Accounts payable | 0.23M | 0.18M | 0.11M | 0.10M | 0.10M |
| Accumulated other comprehensive income | - | - | - | 0.00M | - |
| Non currrent assets other | - | - | - | -0.10M | - |
| Non current assets total | 0.09M | 0.11M | 0.14M | 0.10M | 0.10M |
| Capital lease obligations | 0.00M | 0.01M | 0.03M | 0.03M | 0.03M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-10-31 |
| Investments | - | 0.05M | -0.08M | -0.03M | -0.03M |
| Total cashflows from investing activities | - | 0.05M | -0.08M | -0.03M | - |
| Net borrowings | 0.63M | -0.02M | -0.02M | -0.01M | - |
| Total cash from financing activities | 1.15M | 2.70M | 2.92M | 0.12M | 0.12M |
| Net income | -1.12M | -0.26M | -4.70M | -3.89M | -3.76M |
| Change in cash | 1.68M | 1.12M | -1.06M | -6.10M | -6.10M |
| Begin period cash flow | 5.01M | 3.88M | 4.95M | 11.05M | 11.05M |
| End period cash flow | 6.69M | 5.01M | 3.88M | 4.95M | 4.95M |
| Total cash from operating activities | 0.49M | -1.58M | -3.90M | -6.07M | -6.07M |
| Issuance of capital stock | 0.09M | 0.89M | 1.55M | 0.00M | 0.00M |
| Depreciation | 0.04M | 0.03M | 0.03M | 0.04M | 0.04M |
| Other cashflows from investing activities | - | 0.07M | -0.04M | -0.01M | - |
| Change to inventory | 1.14M | -1.57M | -0.62M | -0.62M | -0.62M |
| Change to account receivables | 0.00M | 0.02M | -0.00M | -0.01M | -0.01M |
| Other cashflows from financing activities | - | 1.83M | 2.94M | 0.14M | - |
| Capital expenditures | 0.02M | 0.01M | 0.05M | 0.03M | 0.03M |
| Change in working capital | 1.57M | -1.20M | -0.81M | -0.53M | -0.53M |
| Stock based compensation | 1.46M | 2.01M | 0.85M | 0.97M | 0.97M |
| Other non cash items | - | -2.15M | 0.72M | 0.12M | 0.12M |
| Free cash flow | 0.48M | -1.59M | -3.95M | -6.09M | -6.09M |
Sector: Consumer Defensive Industry: Household & Personal Products
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| INNPF InnoCan Pharma Corporation |
- -% |
1.29 | - | - | 0.33 | 1.64 | 0.12 | 46.20 |
| PG Procter & Gamble Company |
0.28 0.17% |
168.60 | 23.58 | 22.62 | 4.07 | 7.24 | 4.40 | 16.08 |
| LRLCF L'Oréal S.A |
- -% |
500.60 | 41.14 | 34.25 | 6.52 | 8.59 | 6.67 | 27.76 |
| LRLCY L’Oreal Co ADR |
-0.97 0.96% |
99.66 | 32.44 | 25.64 | 5.16 | 6.03 | 4.79 | 19.51 |
| UL Unilever PLC ADR |
-0.12 0.19% |
66.48 | 21.53 | 16.39 | 2.66 | 7.29 | 2.77 | 12.45 |
InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments, Online sales and Other Operations. The company develops a cannabidiol (CBD)-loaded liposome drug delivery platform (CBD-LPT), which is in the preclinical trial phase to treat chronic pain management for human and veterinary health sectors. It also offers a pain-relieving topical composition, as well as compositions for the treatment of hemorrhoid, psoriasis of the scalp, vaginal atrophy, and diabetic symptoms. The company is also involved in development, manufacture, and marketing of cosmetic products. InnoCan Pharma Corporation was founded in 2017 and is headquartered in Calgary, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Ron Mayron | Exec. Chairman | 1963 |
| Ms. Iris Bincovich | CEO & Director | 1969 |
| Mr. Yoram Drucker | Founder, Exec. VP of Bus. Devel. & Director | 1965 |
| Mr. Nelson Harvey Halpern F.C.A., FCPA | Chief Financial Officer | 1959 |
| Mr. Nir Avram B.Sc., M.Sc. | Chief Technology Officer | NA |
| Mr. Eyal Flom L.L.M., M.B.A. | Director & Company Sec. | 1966 |
| Roni Kamhi | Chief Operating Officer | NA |
| Mr. Moshe Hukaylo | Chief Financial Officer of InnoCan Pharma Ltd. | NA |
| Ms. Iris Bincovich | CEO & Interim Chairwoman | 1969 |
| Mr. Roni Kamhi | COO & Director | 1975 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.66%
Communication Services
-0.37%
Consumer Cyclical
-0.47%
Consumer Defensive
+0.06%
Energy
-0.06%
Financial Services
-0.32%
Financials
-2.20%
Healthcare
-0.89%
Industrials
-0.30%
Real Estate
-0.37%
Technology
-1.29%
Utilities
-0.59%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...